The effect of systemic administration of sclerostin antibody in a mouse model of distraction osteogenesis

Journal of Musculoskeletal Neuronal Interactions

Volumn 14, Issue 1, 2014, Pages 124-130

  Makhdom, Asim M ^a,b,c   Rauch, F ^a   Lauzier, D ^a   Hamdy, R C ^a,b  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Bone regeneration; Distraction osteogenesis; Sclerostin antibody; Wnt signaling

Indexed keywords

PROTEIN ANTIBODY; SCLEROSTIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE MASS; BONE RADIOGRAPHY; BONE REGENERATION; CARTILAGE CELL; CONTROLLED STUDY; DISTRACTION OSTEOGENESIS; DRUG EFFECT; FIBROCARTILAGE; FRACTURE HEALING; HISTOLOGY; IMAGE ANALYSIS; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; QUALITATIVE ANALYSIS; SCORING SYSTEM; SYSTEMIC THERAPY;

ANIMALS; ANTIBODIES; BONE REGENERATION; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; MALE; MICE; OSTEOGENESIS, DISTRACTION;

EID: 84895440825     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Birch JG, Samchukov ML. Use of the Ilizarov method to correct lower limb deformities in children and adolescents. J Am Acad Orthop Surg 2004;12:144-54.
2. Makhdom AM, Hamdy RC. The Role of Growth Factors on Acceleration of Bone Regeneration during Distraction Osteogenesis. Tissue Eng Part B Rev 2013;19(5):442-53.
3. Eldridge JC, Bell DF. Problems with substantial limb lengthening. Orthop Clin North Am 1991;22:625-31.
4. Garcia-Cimbrelo E, Olsen B, Ruiz-Yague M, Fernandez-Baillo N, Munuera-Martinez L. Ilizarov technique. Results and difficulties. Clin Orthop Relat Res 1992:116-23.
5. Velazquez RJ, Bell DF, Armstrong PF, Babyn P, Tibshirani R. Complications of use of the Ilizarov technique in the correction of limb deformities in children. J Bone Joint Surg Am 1993;75:1148-56.
6. Cattermole HC, Cook JE, Fordham JN, Muckle DS, Cunningham JL. Bone mineral changes during tibial fracture healing. Clin Orthop Relat Res 1997:190-6.
7. Mandu-Hrit M, Haque T, Lauzier D, et al. Early injection of OP-1 during distraction osteogenesis accelerates new bone formation in rabbits. Growth Factors 2006;24:172-83.
8. Haidar ZS, Tabrizian M, Hamdy RC. A hybrid rhOP-1 delivery system enhances new bone regeneration and consolidation in a rabbit model of distraction osteogenesis. Growth Factors 2010;28:44-55.
9. Lesaichot V, Leperlier D, Viateau V, Richarme D, Petite H, Sailhan F. The influence of Bone Morphogenic Protein-2 on the consolidation phase in a distraction osteogenesis model. Injury 2011;42:1460-6.
10. Long J, Li P, Du HM, et al. Effects of bone morphogenetic protein 2 gene therapy on new bone formation during mandibular distraction osteogenesis at rapid rate in rabbits. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:50-7.
11. Bishop GB, Einhorn TA. Current and future clinical applications of bone morphogenetic proteins in orthopaedic trauma surgery. Int Orthop 2007;31:721-7.
12. Wozney JM. Overview of bone morphogenetic proteins. Spine (Phila Pa 1976) 2002;27:S2-8.
13. Rengachary SS. Bone morphogenetic proteins: basic concepts. Neurosurg Focus 2002;13:e2.
14. Agholme F, Aspenberg P. Wnt signaling and orthopedics, an overview. Acta Orthop 2011;82:125-30.
15. Kasaai B, Moffatt P, Al-Salmi L, Lauzier D, Lessard L, Hamdy RC. Spatial and temporal localization of WNT signaling proteins in a mouse model of distraction osteogenesis. J Histochem Cytochem 2012;60:219-28.
16. Papapoulos SE. Targeting sclerostin as potential treatment of osteoporosis. Ann Rheum Dis 2011;70 Suppl 1:i119-22.
17. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013;19:179-92.
18. Gamie Z, Korres N, Leonidou A, Gray AC, Tsiridis E. Sclerostin monoclonal antibodies on bone metabolism and fracture healing. Expert Opin Investig Drugs 2012;21:1523-34.
19. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Singledose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26.
20. Chen XX, Baum W, Dwyer D, et al. Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann Rheum Dis 2013;72:1732-6.
21. Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff KM. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res 2013;28:73-80.
22. Gdalevitch M, Kasaai B, Alam N, Dohin B, Lauzier D, Hamdy RC. The effect of heparan sulfate application on bone formation during distraction osteogenesis. PLoS One 2013;8:e56790.
23. Alam N, St-Arnaud R, Lauzier D, Rosen V, Hamdy RC. Are endogenous BMPs necessary for bone healing during distraction osteogenesis? Clin Orthop Relat Res 2009; 467:3190-8.
24. Haque T, Hamade F, Alam N, et al. Characterizing the BMP pathway in a wild type mouse model of distraction osteogenesis. Bone 2008;42:1144-53.
25. Hu J, Li J, Wang D, Buckley MJ, Agarwal S. Differences in mandibular distraction osteogenesis after corticotomy and osteotomy. Int J Oral Maxillofac Surg 2002;31:185-9.
26. Colburn NT, Zaal KJ, Wang F, Tuan RS. A role for gamma/delta T cells in a mouse model of fracture healing. Arthritis Rheum 2009;60:1694-703.
27. Cui L, Cheng H, Song C, et al. Time-dependent effects of sclerostin antibody on a mouse fracture healing model. J Musculoskelet Neuronal Interact 2013;13:178-84.
28. Virdi AS, Liu M, Sena K, et al. Sclerostin antibody increases bone volume and enhances implant fixation in a rat model. J Bone Joint Surg Am 2012;94:1670-80.
29. McDonald MM, Morse A, Mikulec K, et al. Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. J Orthop Res 2012;30:1541-8.
30. Virk MS, Alaee F, Tang H, Ominsky MS, Ke HZ, Lieberman JR. Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J Bone Joint Surg Am 2013;95:694-701.
31. Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 2010;25:2412-8.
32. Ominsky MS, Li C, Li X, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 2011;26:1012-21.
33. Sarahrudi K, Thomas A, Albrecht C, Aharinejad S. Strongly enhanced levels of sclerostin during human fracture healing. J Orthop Res 2012;30:1549-55.